IK Investment Partners to support Mabtech
IK Investment Partners (“IK”) is pleased to announce that the IK Small Cap II Fund has reached an agreement to acquire Mabtech, a leading specialist in immune monitoring. The founders and management team will continue to be invested. Merieux Equity Partners (“MxEP”) will acquire a minority stake alongside the Fund. Financial terms of the transaction are not disclosed. Founded in Sweden in 1986, Mabtech has gained worldwide recognition for its high quality monoclonal antibodies and technical innovation capabilities and is viewed as a pioneer within the growing detection platform